Annual Report 2023

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2023 153 The United Laboratories International Holdings Limited Annual Report 2023 46. INFORMATION ABOUT THE STATEMENT OF FINANCIAL POSITION OF THE COMPANY (Continued) (b) Reserves Share premium Treasury stock Share- based compensation reserve Retained profits Total RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 At 1 January 2022 3,782,428 (17,815) – 315,549 4,080,162 Profit and total comprehensive income for the year – – – 1,426,050 1,426,050 Dividends recognised as distribution (Note 15) – – – (272,636) (272,636) Repurchase and cancellation of shares (59,946) 18,062 – – (41,884) Transaction costs attributable to repurchase and cancellation of shares – (247) – – (247) At 31 December 2022 3,722,482 – – 1,468,963 5,191,445 Profit and total comprehensive income for the year – – – 173,633 173,633 Dividends recognised as distribution (Note 15) – – – (581,448) (581,448) Recognition of share-based compensation expense – – 6,365 – 6,365 At 31 December 2023 3,722,482 – 6,365 1,061,148 4,789,995